Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$2.79
+1.5%
$2.90
$2.01
$6.33
$350.79M2.062.84 million shs9.77 million shs
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
$0.39
+19.9%
$0.41
$5.00
$13.51
$2.00M0.1839,705 shs702,058 shs
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$7.15
$7.13
$1.08
$7.19
$373.81M1.661.70 million shsN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
$2.05
-5.5%
$2.17
$1.15
$6.48
$74.55M4.08586,716 shs1.11 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
+1.45%+0.36%+3.33%-7.31%-19.83%
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
0.00%+4.57%-4.82%-28.35%-68.54%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
0.00%0.00%0.00%0.00%+179.30%
Inotiv, Inc. stock logo
NOTV
Inotiv
-5.53%-7.66%+1.49%-25.45%+17.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Absci Corporation stock logo
ABSI
Absci
2.0336 of 5 stars
3.51.00.00.02.21.70.6
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
0.4467 of 5 stars
1.00.00.03.80.00.00.6
Inotiv, Inc. stock logo
NOTV
Inotiv
1.8175 of 5 stars
3.51.00.00.01.90.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Corporation stock logo
ABSI
Absci
3.00
Buy$8.40201.08% Upside
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
0.00
N/AN/AN/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
2.00
Hold$4.00-44.06% Downside
Inotiv, Inc. stock logo
NOTV
Inotiv
3.00
Buy$5.00143.90% Upside

Current Analyst Ratings Breakdown

Latest NOTV, ABSI, DKDCA, and GTHX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Absci Corporation stock logo
ABSI
Absci
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
5/8/2025
Inotiv, Inc. stock logo
NOTV
Inotiv
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $5.00
4/16/2025
Absci Corporation stock logo
ABSI
Absci
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $9.00
4/9/2025
Absci Corporation stock logo
ABSI
Absci
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Corporation stock logo
ABSI
Absci
$4.53M78.56N/AN/A$1.56 per share1.79
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
N/AN/A$0.00 per share111.42($1.82) per shareN/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$58.20M6.42N/AN/A$0.68 per share10.51
Inotiv, Inc. stock logo
NOTV
Inotiv
$490.74M0.14$1.45 per share1.41$6.55 per share0.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Corporation stock logo
ABSI
Absci
-$103.11M-$0.92N/AN/AN/A-2,232.13%-53.69%-45.89%8/13/2025 (Estimated)
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
$340K-$0.19N/AN/AN/AN/A-5.55%N/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/A
Inotiv, Inc. stock logo
NOTV
Inotiv
-$108.44M-$3.19N/AN/AN/A-18.21%-15.64%-3.44%8/6/2025 (Estimated)

Latest NOTV, ABSI, DKDCA, and GTHX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Absci Corporation stock logo
ABSI
Absci
-$0.23-$0.21+$0.02-$0.21$1.07 million$1.18 million
5/7/2025Q2 2025
Inotiv, Inc. stock logo
NOTV
Inotiv
-$0.24-$0.18+$0.06-$0.44$123.97 million$124.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Corporation stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
N/AN/AN/AN/AN/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Corporation stock logo
ABSI
Absci
N/A
5.72
5.72
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
N/AN/AN/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
1.34
2.48
2.12
Inotiv, Inc. stock logo
NOTV
Inotiv
2.49
1.50
1.18

Institutional Ownership

CompanyInstitutional Ownership
Absci Corporation stock logo
ABSI
Absci
52.05%
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
35.35%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
24.21%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%

Insider Ownership

CompanyInsider Ownership
Absci Corporation stock logo
ABSI
Absci
10.49%
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
45.72%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
6.11%
Inotiv, Inc. stock logo
NOTV
Inotiv
7.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Corporation stock logo
ABSI
Absci
210127.56 million114.18 millionOptionable
Data Knights Acquisition Corp. stock logo
DKDCA
Data Knights Acquisition
25.17 million2.81 millionNot Optionable
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
17052.28 million49.09 millionOptionable
Inotiv, Inc. stock logo
NOTV
Inotiv
2,07534.35 million31.67 millionOptionable

Recent News About These Companies

Inotiv Cleared by SEC in Importation Probe
Inotiv Inc.
Lake Street Remains a Buy on Inotiv (NOTV)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Absci stock logo

Absci NASDAQ:ABSI

$2.79 +0.04 (+1.45%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$2.78 -0.01 (-0.36%)
As of 06/20/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Data Knights Acquisition stock logo

Data Knights Acquisition NASDAQ:DKDCA

$0.39 +0.06 (+19.93%)
As of 06/16/2025

Data Knights Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. Data Knights Acquisition Corp. was incorporated in 2021 and is based in Frome, the United Kingdom.

G1 Therapeutics stock logo

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Inotiv stock logo

Inotiv NASDAQ:NOTV

$2.05 -0.12 (-5.53%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$2.04 0.00 (-0.24%)
As of 06/20/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.